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Opioids are widely misused and account for almost half of overdose deaths in the United 
States. The cost in terms of lives, health care, and lost productivity is significant and has been 
declared a national crisis. Fentanyl is a highly potent mu opioid receptor (MOR) agonist and plays 
a significant role in the current opioid epidemic; Fentanyl and its analogs (fentalogs) are 
increasingly becoming one of the biggest dangers in the opioid crisis. The presence of fentalogs in 
the illicit market is thought to play a significant role in the recent increase in opioid-related deaths. 
Although there is both rodent homolog in vivo and in vitro data for some fentalogs, prior to this 
publication very little was known about the pharmacology of many of these illicit compounds at 
the human MOR (hMOR). Using GC-MS, NMR spectroscopy, and in vitro assays, this study 
describes the spectral and pharmacological properties of 34 fentalogs. The reported spectra and 
chemical data will allow for easy identification of novel fentalogs in unknown or mixed samples. 
Taken together these data are useful for law enforcement and clinical workers as they will aid in 
identification of fentalogs in unknown samples and can potentially be used to predict physiological 
effects after exposure. 
1. Introduction: 
Over the past decade, the medical, economic, and social cost of the opioid crisis has 
increased steadily in the United States (U.S.).1-5 This is due, in part, to the increased number of 
opioid prescriptions written since the 1990s; one recent estimate states that almost 290 million 
opioid prescriptions are written in the U.S. annually.6 In 2017, there were nearly 48,000 opioid 
related deaths in the U.S.,7 which was more than the number of automobile accident fatalities.8 
The opioid crisis was estimated to have cost the US over $600 billion from 2015-2019.9 
Initially, prescription opioid analgesics made up the majority of abused opioids, this was 
dubbed the first wave of the opioid epidemic by the United States Centers for Disease Control. 
However, after 2010, heroin became the largest contributor to opioid related deaths, the second 
wave of the opioid epidemic, as opioid drug users transitioned away from prescription opioids as 
they became more difficult to acquire.10 Recently the third wave of the opioid epidemic has 
emerged, synthetic opioids such as Fentanyl have been found increasingly in the illicit drug supply, 
in heroin and false prescription opioid samples, and also in samples containing stimulants such as 
cocaine or amphetamine.11 In addition to Fentanyl, structurally related Fentanyl analogs 
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(fentalogs) have been used to adulterate illicit drug samples and, in some cases, have been 
administrated as the primary drug of use.12-14 As a result, Fentanyl is subject to core US Drug 
Enforcement Administration scheduling and all illicit Fentanyl analogs are considered Schedule I 
compounds. 
Clinically used opioid analgesics and illicit opioids all exert their physiological actions 
through stimulation of the mu opioid receptor (MOR).15-17 Agonist activity at MOR produces not 
only the clinically desirable analgesic properties of opioids, but also euphoria, a significant 
contributor to addiction, and respiratory depression, the presumed main cause of morbidity from 
opioid overdose.18-20 Further, elimination of MOR by knock-out in rodents prevents morphine, a 
prototypical opioid agonist, from producing respiratory depression.21 The kappa opioid receptor 
(KOR) and the delta opioid receptor (DOR) have not been shown to have significant influence on 
respiration.21  It is noteworthy that Fentanyl’s ability to produce opioid-induced respiratory 
depression exceeds that of common painkillers such as morphine or other similar morphinan 
compounds.22 Further, Fentanyl is known to cause severe muscle rigidity, which likely exacerbates 
the acute toxicity of Fentanyl and its analogs.23 While it is known that Fentanyl is a potent agonist 
at rat, human, and marmoset MOR, most of the novel, illicit fentalogs in this investigation have 
no previously reported data at the human MOR (hMOR).  
The clinical relevance of in vitro studies at the human opioid receptors cannot be 
overlooked. Over the last several decades, fentalogs have been pharmacologically characterized 
primarily in rodent models.24-39 Much of the fentalog data collected in this area is represented by 
in vivo experiments where pharmacokinetic parameters make comparative evaluation difficult. In 
these studies, the fentalogs displayed a wide range of ED50s relative to Fentanyl.
24 By comparison, 
in vitro data on fentalogs have been scarce, with few recent reports.31-40 The use of brain 
homogenate and membrane preparations of rats have been classically the primary avenue for in 
vitro potency testing of fentalogs,25,26,29,30 however these studies often come with caveats, as these 
experiments do not examine direct effects at a single receptor, but are complicated by the presence 
of multiple receptors, metabolizing enzymes, etc. By comparison, the use of cell lines 
overexpressing a single receptor, hMOR, for in vitro characterization of fentalogs has gone largely 
uninvestigated. Data at the human receptors (as opposed to rodent or other species) are valuable 
and have potential to more accurately reflect the effects of these compounds on human subjects. 
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In this report we characterize 34 fentalogs of interest (Figure 1, Table 1), for the law 
enforcement community using cell systems overexpressing hMOR and highlight their structure 
activity relationships (SAR). These samples were chosen to reflect compounds commonly 
requested by forensic laboratories as they are likely representative of what is found in samples 
gathered in search and seizure by law enforcement. We report the affinities, agonist activity, and 
potencies of these Fentanyl analogs at the hMOR, as well as their GC-MS, NMR, and IR spectral 
data. This novel data can be of importance to the law enforcement, emergency responder, and 
regulatory communities. 
 
2. Methods and Materials 
2.1 Synthesis of Fentalogs  
Materials. All solvents were purchased from Millipore Sigma. Synthetic reagents were purchased 
from TCI America, Millipore Sigma, Asta-Tech Inc., Oakwood Chemicals, Alfa Aesar, and AK 
Scientific and used without further purification. 
All compounds were synthesized using methods from previously reported synthetic work.41,42 
Chemical structures were determined using gas chromatography-mass spectrometry (GC-MS), 
flow injection analysis mass spectrometry (FIA-MS), liquid chromatography mass spectrometry 
(LC-MS), proton nuclear magnetic resonance spectroscopy (1H-NMR), carbon nuclear magnetic 
resonance (13C-NMR), infrared spectroscopy (FT-IR), and melting point. Purities were assessed 
using high performance liquid chromatography (HPLC) and 1H-NMR. All final compounds were 
purified to >98%, in accordance with industry standards. Synthesis methods and full 
characterization of compounds may be found in the supplemental section. 
2.2 Gas Chromatography-Mass Spectrometry (GC-MS) 
2.2a Sample Preparation: Each compound was dissolved in HPLC-grade methanol (Sigma 
Aldrich) to produce a 1.0 mg/mL solution, of which 1.0 µL was used for sample injection. 
2.2b Instrumentation:  All samples were characterized by GC-MS using an Agilent 6890 Gas 
chromatograph equipped with an Agilent 5973 Mass Selective Detector. The attached column was 
a Restek, Rtx-5 MS, 30 m x 0.32 mm I.D., with 0.5 µm film thickness (phase composition: 
crossbond 5% diphenyl / 95% dimethyl polysiloxane).  
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2.2c Methods and Parameters: The temperature of the injector was maintained at constant flow at 
300 ºC. The oven temperature was started at 240 ºC for one min, then increased by 30 ºC/min to 
300 ºC where holding time was 27 min (30 min total run time). Helium was used as the carrier gas 
at 2.0 mL/min (split ratio: 15:1). Mass spectrometer settings: Transfer line = 300 ºC, MS source = 
230 ºC, MS quad = 150 ºC, scan range: m/z 40-600, electron ionization = 70 eV. More details on 
the GC parameters can be found in supplemental-S4. 
2.3 Proton Nuclear Magnetic Resonance (1H-NMR) Spectroscopy 
Sample Preparation and Instrumentation: Samples were prepared as ~5 mg/mL solutions in 
deuterium-labelled chloroform (Acros Organics), dimethylsulfoxide (Cambridge Isotope 
Laboratories), or methanol (CDN Isotopes). 1H-NMR spectra were measured on a Varian Unity 
Inova 400 MHz spectrometer. Chemical shifts were reported in parts per million (ppm). Results 
can be found in supplemental-S2. 
2.4 Melting Point (MP) 
Sample Preparation and Instrumentation: Samples were prepared using neat solids and Kimble 
capillary tubes (1.5 mm x 90 mm). Melting point ranges were measured using an Electrothermal 
Digital Melting Point Apparatus, using a 1°/minute ramping method. Start temperature is the 
temperature at which the solid first begins to change from a dry solid; final temperature is the 
temperature at which the solid is completely melted to a homogeneous fluid. Results can be found 
in supplemental-S2. 
2.5 Fourier-Transform Infrared Spectroscopy (FT-IR) 
Sample Preparation and Instrumentation: Samples were prepared as neat solids that were set 
directly on top of the detector. IR spectra were collected using a Perkin Elmer Spectrum 65 FT-IR 
Spectrometer, and the data were reported in wavenumbers (cm-1). Results can be found in 
supplemental-S2. 
2.6 In Vitro Characterization of Fentalogs 
2.6.1 Cell Lines and Membrane Preparations: All tissue culture reagents were purchased from 
Gibco Life Sciences, Fisher Scientific, or Sigma-Aldrich unless otherwise noted. Radio-labeled 
ligands were purchased from Perkin Elmer. Chinese hamster ovary (CHO) cells stably expressing 
a human µ (hMOR) in a pcDNA 3.1 vector using geneticin as the selection agent were used for all 
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in vitro assays. These cells stably express hMOR at 4240 fmoles of receptor/mg of protein. This 
cell line was generously provided by Dr. Lawrence Toll.43  
Cells were grown to confluence at 37 ºC in 5% CO2 in Dulbecco’s Modified Eagle’s Medium: F12 
Ham (1:1 mixture) containing 10% v/v fetal bovine serum and 5% v/v penicillin/streptomycin. 
Membranes were prepared by washing confluent cells three times with ice cold phosphate-buffered 
saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells were detached from the 
plates by incubation in warm harvesting buffer (20 mM HEPES, 150 mM NaCl, 0.68 mM EDTA, 
pH 7.4) and pelleted by centrifugation at 200xg for 3 min. The cell pellet was suspended in ice-
cold 50 mM Tris-HCl buffer, pH 7.4 and homogenized with a Tissue Tearor (Biospec Products) 
for 20 sec at setting 4. The homogenate was centrifuged at 20,000xg for 20 min at 4 ºC, and the 
pellet was rehomogenized in 50 mM Tris-HCl pH 7.4 with a Tissue Tearor for 10 sec at setting 2, 
followed by recentrifugation. The final pellet was resuspended in 50 mM Tris-HCl, pH 7.4 and 
frozen in aliquots at -80 ºC. Protein concentration was determined via Pierce BCA protein assay 
kit using bovine serum albumin as the standard. 
2.6.2 Radioligand Competition Binding Assays: Assays were performed using competitive 
displacement of 0.2 nM [3H]diprenorphine (250 µCi, 1.85TBq/mmol, KD at hMOR 0.38 nM), a 
nonselective opioid ligand, by the test fentalog from membrane preparations stably expressing 
hMOR. The assay mixture, containing membranes (approximately 5 μg protein/tube) in 50 mM 
Tris-HCl buffer (pH 7.4), [3H]diprenorphine, and various concentrations of test fentalog, was 
incubated on a shaker at r.t. for 1 h to allow binding to reach equilibrium. The samples were filtered 
through Whatman GF/C filters and washed three times with 50 mM Tris-HCl buffer (pH 7.4). The 
radioactivity retained on dried filters was determined by liquid scintillation counting after 
saturation with EcoLume liquid scintillation cocktail in a 2450 MicroBeta2 (Perkin-Elmer). 
Nonspecific binding was determined using 10 μM naloxone; total binding was determined using 
water. The results presented are the mean ± SEM from three individual assays performed on three 
different days. Each individual assay is performed in duplicate and then averaged. The data were 
fitted to a one-site, non-linear regression curve (one site competition binding curve) using 
GraphPad Prism v8.02, IC50 values were converted to Ki values using the Cheng-Prusoff 
equation.44  
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2.6.3 Stimulation of GTPγ[35S] Binding: Agonist stimulation of [35S]guanosine5'-O-[gamma-
thio]triphosphate ([35S]GTPγS, 1250 Ci, 46.2TBq/mmol) binding was measured. Membranes (10 
μg of protein/tube) were incubated 1 h at r.t. in GTPγS buffer (50 mM Tris-HCl, 100 mM NaCl, 
10 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1 nM [
35S]GTPγS, 30 μM guanosine 
diphosphate (GDP), and varying concentrations of test fentalog. Test fentalog stimulation of 
[35S]GTPγS was compared with 10 μM standard MOR agonist [D-Ala2, N-MePhe4, Gly-ol]-
enkephalin  (DAMGO). The reaction was terminated by rapidly filtering through GF/C filters and 
washing five times with GTPγS buffer. Retained radioactivity was measured as described above. 
The results presented are the mean ± SEM from three individual assays performed on three 
different days. Each individual assay is performed in duplicate and then averaged. The data were 
fitted to a non-linear regression curve (sigmoidal dose response curve for agonist stimulation) 
using GraphPad Prism v8.02. 
2.6.4 Data Collection. All in vitro assays were run in duplicate in 3 or more individual assay. Data 
are presented as the mean ± SEM for all data points. Data for all in vitro competition binding 
assays are normalized such that basal (in the presence of 10 µM naloxone) and total binding (in 
the absence of any drug) are set to zero and 100 percent binding respectively. Data for all in vitro 
[35S]GTPγS assays are normalized such that basal (in the absence of drug) and total (in the presence 
of  10 µM standard agonist DAMGO) are set to zero and 100 percent stimulation respectively. 
This normalization is used to account for variation between membrane preparations or assays. 
 
3. Results and Discussion 
3.1 In Vitro Pharmacological Data: Agonist binding affinity and efficacy at hMOR 
The binding affinity (Ki) and agonist efficacy (% stimulation and EC50) of 34 fentalogs were 
determined at hMOR (Table 2). Competition binding assay using [3H]diprenorphine and 
membranes stably overexpressing hMOR was used to determine binding affinity of fentalogs. The 
[35S] GTPγS binding assay was used to determine efficacy data in terms of % max stimulation and 
potency (EC50) relative to the standard agonist DAMGO. Using this data, the SAR of all 34 
fentalogs was compared. As a point of comparison, morphine was also tested: Ki 4.2 ± 0.13 nM, 
% stimulation 99 ± 4 %, EC50 150 ± 50 nM. 
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As expected, Fentanyl (1) displays tight binding (1.6 ± 0.4 nM) and full agonist activity (89 ± 9% 
of DAMGO, a prototypical MOR agonist) at hMOR. This is consistent with previous studies of 
Fentanyl at both the human and marmoset MOR.45,46 
Modifications at Region A (2-22, Table 2) sampled both constrained (2-7) and flexible moieties 
(8-22). In general, the majority of these compounds displayed single digit nanomolar affinity for 
hMOR, with a few notable exceptions. Acetyl fentanyl (8), which contains only a methyl group in 
Region A, has much lower affinity for the hMOR (64 nM) as compared to Fentanyl (1, 1.6 nM). 
Similarly, analogs 9 and 10 (also a methyl in Region A) display weaker binding at hMOR (Ki 43 
nM and 19 nM respectively). This suggests that Region A has minimum bulk requirements to 
maintain optimal contact with the orthosteric binding site of hMOR. There is, however, some 
flexibility in terms of how large a group can be accommodated in the Region A, the 4-carbon tert-
butyl group (19) and the 5-carbon cyclopentyl group (5) both bind well to hMOR (4.5 nM and 6.6 
nM respectively). While increased bulk at R1 had little effect on binding affinity when increasing 
ring size (2, 4, and 5), a large difference in EC50 potency was observed (55 nM, 160 nM, and 600 
nM respectively).  
The presence of an oxygen in Region A seems to effect binding. One example is Tetrahydrofuran 
fentanyl (7) which displays decreased binding affinity (31 nM) at the hMOR relative to 
Cyclopentyl fentanyl (5) (6.6 nM). The EC50 of 7 (390 nM) was 12-fold less potent than Fentanyl 
(1) (32 nM), and the G protein simulation was decreased to 36%.  Another direct comparison can 
be made between Methoxyacetyl fentanyl (22) (17 nM) and Butyryl fentanyl (20) (3.5 nM). 
Compound 22 with non-aromatized lone pairs of electrons displays decreased binding at hMOR 
which could suggest that H bond acceptors are not well tolerated in Region A. Interestingly, in 
comparison to 7 and 22, compound 6 (Furanyl fentanyl) shows that aromaticity in Region A forms 
favorable interactions in the orthosteric binding site of hMOR (1.3 nM).  
Modifications at Region B (23-29, Table 2) compared both a halogen and a methyl substituent at 
the ortho, meta, and para positions. A chlorine in the para-position of Region B drastically 
decreased hMOR binding (45 nM; para-Chloro fentanyl, 29), while a para-methyl did not (4.2 
nM; para-Methyl fentanyl, 28), suggesting a complex interaction between electronics and bulk. 
The relatively low EC50 potency seen in 29 (>1000 nM) is consistent with previous mouse ED50 
data.24 This trend appears to be further demonstrated with para-Chloro isobutyryl fentanyl (18) 
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which shows a greater than 50-fold decrease in binding affinity compared to Fentanyl (1) (82 nM 
vs 1.6 nM). In addition, the EC50 of 18 (>2000 nM) is greater than 60-fold less potent than Fentanyl 
(1) at hMOR. These data suggest that a large halogen substituent at the para-position of Region B 
has a weakening effect on binding affinity and potency. The addition of a fluorine in the meta or 
para positions on the aniline ring of Region B tend to decrease potency and efficacy at hMOR.  In 
contrast, the addition of a fluorine in the ortho position increases potency and efficacy at hMOR 
(1 vs 23, 11 vs 12, 14 vs 15, and 20 vs 21). This suggests that electronic density of the aromatic 
ring in Region B are important for making contact with the active conformation of hMOR. An 
ortho-fluorine on Region B increases the agonist character of fentalogs in all instances. 
Modifications at Region C have been studied extensively using in vivo and in vitro rodent models 
and contains a subset of highly hazardous fentalogs including 3 and 4-position substituted analogs 
such as Carfentanil, Ohmefentanyl, and enantiomerically pure (+)-cis-3-Methyl fentanyl.47-49 In 
this study, (+/-)-cis-3-Methyl fentanyl (30) was used in an attempt better emulate what may be 
found on the illicit market. As expected, compound 30 demonstrated a 5-fold higher affinity for 
hMOR than Fentanyl (1) (0.3 nM vs 1.6 nM). Other modifications in Region C (31-34), did not 
dramatically alter binding affinity at hMOR; the greatest deviation from Fentanyl (1) was seen in 
β-Methyl fentanyl (34) which displayed an almost 10-fold decrease in affinity (14 nM). These data 
further confirm that substitutions on the piperidine ring yield the greatest binding affinity and 
potency increases in the samples tested. 
3.2 Structural Analysis Through GC-MS  
The mass-spectral fragmentation of Fentanyl and many of its analogs have been previously 
reported.50-53 Much attention is paid to the interpretation of EI-MS due to the routine use of GC-
MS in forensic labs. The four most abundant EI-MS fragment ions in the GC-MS of the fentalogs 
in this study are listed in Table 3.  As expected, and as previously reported, the base peak is 
typically the result of α-β cleavage of the phenethyl C-C bond (Region C).54-56  In Fentanyl (1), 
the base peak is m/z 245.  Consistent with previous findings was the further fragmentation of the 
base peak yielding the characteristic 189 and 146 fragment ions as shown in Figure 2A.54-57 The 
presence of the m/z 189, 146, and 91 fragments yields structural information as to where new 
Fentanyl analogues may or may not have been modified. 
This article is protected by copyright. All rights reserved.
10 
 
Of the 34 fentalogs evaluated, m/z 245 and m/z 259 were the most commonly observed base peaks 
with the base peak 259 representing the substitution of an H for a CH3 (methyl) as shown in Figure 
2B (additional CH3 shown in blue). The base peak m/z 259 is observed in compounds 14, 20, 26-
28, 30 and 31. 
One notable observation in the EI-MS data of the fentalogs tested is the presence of the m/z 164 
fragment which indicates that a single fluorine has been installed on the Fentanyl scaffold 
(depicted in red, Figure 2C and Table 3). All of the studied fentalogs producing the m/z 164 
fragment (12-13, 15-16, 21 and 23-25) displayed EC50s of less than 100 nM and/or >80% G protein 
stimulation at hMOR (Table 2).  This is consistent with literature reports of other fluorinated 
fentalogs, such as NFEPP, which contains a fluorine in the 3-position on the piperidine ring and 
has been reported to be a highly potent MOR agonist.58  The observed correlation between the 
addition of a fluorine (at either Region B or at the 3-position in Region C) with high potency at 
MOR highlights the need to carefully handle fentalogs containing a m/z 164 fragment ion. 
While it is a rapid means of identification, GC-MS is not the only analytical technique which can 
be used to identify fentalogs; 1H- and 13C-NMR spectroscopy can also be employed to survey 
unknown samples for the presence of common fentalogs of abuse. 
3.3 Structural Analysis Through 1H-NMR Spectroscopy  
While the 1H-NMR spectra of the studied fentalogs displayed many variances in both the aromatic 
and aliphatic regions, the spectra showed commonalities that were characteristic among a majority 
of the fentalogs tested.59 The most notable characteristic peak among all of the fentalogs was a 
triplet of triplets (most often viewed as multiplet), positioned between 4.65 ppm and 4.85 ppm. 
This peak represents the single proton on the 4-position of the piperidine ring and is present in all 
fentalogs in this study (supplemental-S2). Further upfield, a group of four signals including two 
broad doublets (1.9 ppm and 3.0 ppm), a broad triplet (2.2 ppm), and a quartet of doublets (1.5 
ppm) can be seen and distinguished in most cases. These each integrate to two protons and are 
indicative of the eight protons associated with the piperidine ring, excluding the 4-position. There 
is also a set of mirror image multiplets (2.55 ppm – 2.78 ppm), which is characteristic of the four 
protons on the phenethyl chain (α/β positions in Region C). Chemical shifts of all fentalogs 
included in this study can be found in the supplemental-S2 data section as well as corresponding 
13C-NMR data. 




In this report we describe the spectroscopic analysis and in vitro pharmacology of a series of 
fentalogs. The pharmacological data presented in this report describe the structural features that 
convey potent hMOR agonism on the Fentanyl scaffold, which could aid in predicting relative 
potencies of new analogs. In general, it should be noted that compounds containing an ortho-fluoro 
substituent in Region B display strong agonist character at hMOR and could be especially 
hazardous upon exposure.  
Both binding affinity and potency are affected by the size of substitutions in Region A. Compounds 
that have very large or very small Region A moieties tend to have lower affinity and potency, 
suggesting that the parent scaffold which contains an ethyl group in Region A provides optimal 
contact with the active conformation of hMOR. Both the sterics and electron density of the Region 
B substituent impact the affinity and agonist activity of fentalogs. Compounds with ortho-fluoro 
substitutions in Region B showed improved binding affinity and efficacy at MOR as compared to 
Fentanyl making them potentially hazardous, whereas para-chloro substituents decreased potency.   
The GC-MS analysis highlighted the common molecular ion fragments of m/z 146 and m/z 189 
that are indicative of many fentalogs. All potent fentalogs with a m/z 164 fragment ion contained 
a fluorine in Region B or the piperidine ring of Region C. In addition, the 1H-NMR analysis 
demonstrated shared coupling and splitting patterns in the aliphatic region among all fentalogs 
tested, which can be used for identification and differentiation of fentalogs in unknown samples.  
Taken together, these data may help to guide government regulating bodies and law enforcement 
communities in identifying fentalogs in unknown samples as well as aid in safe handling practices 
when encountering potential high potency analogs. This information has the potential to aid in 
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Name Compound # R1 R2 R3 R4 R5
Fentanyl 1 ethyl H H α -H, β -H phenyl
Cyclopropyl fentanyl 2 cyclopropyl H H α -H, β -H phenyl
p -Methyl cyclopropyl fentanyl 3 cyclopropyl p -methyl H α -H, β -H phenyl
Cyclobutyl fentanyl 4 cyclobutyl H H α -H, β -H phenyl
Cyclopentyl fentanyl 5 cyclopentyl H H α -H, β -H phenyl
Furanyl fentanyl 6 2-furanyl H H α -H, β -H phenyl
Tetrahydrofuran fentanyl 7 2-tetrahydrofuranyl H H α -H, β -H phenyl
Acetyl fentanyl 8 methyl H H α -H, β -H phenyl
o -Methyl acetyl fentanyl 9 methyl o -methyl H α -H, β -H phenyl
α -Methyl acetyl fentanyl 10 methyl H H α -methyl, β -H phenyl
Acryl fentanyl 11 ethylene H H α -H, β -H phenyl
o -Fluoro acryl fentanyl 12 ethylene o -fluoro H α -H, β -H phenyl
p -Fluoro acryl fentanyl 13 ethylene p -fluoro H α -H, β -H phenyl
Isobutyryl fentanyl 14 isopropyl H H α -H, β -H phenyl
o -Fluoro isobutyryl fentanyl 15 isopropyl o -fluoro H α -H, β -H phenyl
m-Fluoro isobutyryl fentanyl 16 isopropyl m-fluoro H α -H, β -H phenyl
p -Fluoro isobutyryl fentanyl 17 isopropyl p -fluoro H α -H, β -H phenyl
p -Chloro isobutyryl fentanyl 18 isopropyl p -chloro H α -H, β -H phenyl
Pivaloyl fentanyl 19 tert -butyl H H α -H, β -H phenyl
Butyryl fentanyl 20 propyl H H α -H, β -H phenyl
o -Fluoro butyryl fentanyl 21 propyl o -fluoro H α -H, β -H phenyl
Methoxyacetyl fentanyl 22 methoxy methylene H H α -H, β -H phenyl
o -Fluoro fentanyl 23 ethyl o -fluoro H α -H, β -H phenyl
m-Fluoro fentanyl 24 ethyl m-fluoro H α -H, β -H phenyl
p -Fluoro fentanyl 25 ethyl p -fluoro H α -H, β -H phenyl
o -Methyl fentanyl 26 ethyl o -methyl H α -H, β -H phenyl
m-Methyl fentanyl 27 ethyl m-methyl H α -H, β -H phenyl
p -Methyl fentanyl 28 ethyl p -methyl H α -H, β -H phenyl
p -Chloro fentanyl 29 ethyl p -chloro H α -H, β -H phenyl
cis -3-Methyl fentanyl 30 ethyl H cis -methyl α -H, β -H phenyl
trans -3-Methyl fentanyl 31 ethyl H trans -methyl α -H, β -H phenyl
Furanylethyl fentanyl 32 ethyl H H α -H, β -H 2-furan
β -Hydroxy thiofentanyl 33 ethyl H H α -H, β -OH 2-thiophene
β -Methyl fentanyl 34 ethyl H H α -H, β -methyl phenyl




Table 2. In vitro binding affinity and efficacy data at hMOR for fentalogs with modifications at 
Region A or Region A & B (purple), Region B (blue), and Region C (yellow). All values are 
expressed as mean ± SEM of at least three separate assays performed in duplicate. 
Binding Affinity




EC50 nM          
(SEM)
1 1.6 (0.4) 89 (9) 32 (8)
2 2.4 (0.4) 75 (6) 55 (10)
3 7.2 (1.7) 61 (4) >1000
4 5 (1) 41 (5) 160 (30)
5 6.6 (0.7) 56 (5) 600 (190)
6 1.3 (0.07) 20.4 (2.9) 9.3 (1.9)
7 31 (6) 36 (2) 390 (96)
8 64 (15) 49 (6) >2000
9 43 (10) 43 (2) >1000
10 19 (3) 53 (7) >500
11 2.1 (0.04) 77.9 (1.4) 68 (16)
12 1.1 (0.5) 81 (6) 14 (1)
13 4.3 (0.9) 82 (12) 84 (11)
14 6.6 (1.3) 96 (11) 137 (13)
15 1.3 (0.02) 102 (7) 42 (13)
16 4.5 (0.4) 95 (12) >500
17 24 (4) 82 (16) >1000
18 82 (17) >65 >2000
19 4.5 (0.7) 64 (8) 531 (136)
20 3.5 (0.3) 45 (10) 80 (22)
21 0.7 (0.06) 50 (6) 60 (15)
22 17 (5) 54 (5) >500
23 0.4 (0.1) 87 (5) 15 (4)
24 10.0 (0.3) 50 (1) 164 (24)
25 4.2 (0.3) 48 (10) 79 (22)
26 3.4 (0.3) 69 (2) 58 (10)
27 5.5 (0.8) 52 (7) 450 (75)
28 4.2 (0.7) 31 (3) >1000
29 45 (9) 40 (3) >1000
30 0.32 (0.06) 100 (8) 4.2 (0.6)
31 1.1 (0.2) 93 (4) 25 (6)
32 8 (1) 76 (5) 350 (7)
33 6.2 (0.7) 83 (5) 138 (21)
34 14 (1) 86 (3) >500
Compound        
#
Efficacy




Table 3. GC-MS fragmentation of fentalogs. Parent compounds and their fragments are 
organized in order of descending base peak number. Red highlights the fluorinated analogs with 
the m/z 164 fragment.  
 
Compound RT (min.) Base Peak (m/z ) Fragmentation (m/z ) EC50 (SEM) nM
18 12.79 293 43, 180, 223, 293 >2000
7 14.41 287 71, 146, 189, 287 390 (96)
5 13.92 285 69, 146, 189, 285 600 (190)
29 12.88 279 57, 180, 223, 279 >1000
15 11.32 277 43, 164, 207, 277 42 (13)
16 11.06 277 43, 164, 207, 277 >500
21 11.82 277 43, 164, 207, 277 60 (15)
17 11.85 273 105, 160, 203, 273 >1000
3 12.84 271 69, 160, 203, 271 >1000
4 13.24 271 55, 146, 189, 271 160 (30)
23 11.57 263 57, 164, 207, 263 15 (4)
24 11.39 263 57, 164, 207, 263 164 (24)
25 11.39 263 57, 164, 207, 263 79 (22)
12 11.72 261 55, 164, 218, 261 14 (1)
13 11.48 261 55, 164, 218, 261 84 (11)
22 12.48 261 45, 105, 158, 261 >500
14 11.49 259 43, 146, 189, 259 137 (13)
20 11.83 259 105, 146, 189, 259 80 (22)
26 12.08 259 91, 160, 203, 259 58 (10)
27 11.84 259 91, 160, 203, 259 450 (75)
28 12.29 259 105, 160, 203, 259 >1000
30 11.78 259 105, 160, 203, 259 4.2 (0.6)
31 11.66 259 91, 105, 160, 259 25 (6)
2 12.44 257 69, 146, 189, 257 55 (10)
Fentanyl (1) 11.80 245 91, 146, 189, 245 32 (8)
9 11.67 245 91, 160, 202, 245 >1000
10 11.57 245 56, 91, 110, 245 >500
32 10.85 245 57, 146, 189, 245 350 (7)
33 13.21 245 93, 146, 189, 245 138 (21)
34 11.53 245 91, 146, 189, 245 >500
11 11.73 243 55, 146, 200, 243 68 (16)
8 10.72 231 91, 146, 188, 231 >2000
6 14.24 95 95, 187, 240, 283 9.3 (1.9)
19 11.87 57 57, 105, 146, 273 531 (136)
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